Human medicines European public assessment report (EPAR): Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, HIV Infections, Date of authorisation: 31/08/2014, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, HIV Infections, Date of authorisation: 31/08/2014, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Prostatic Neoplasms, Castration-Resistant, Date of authorisation: 09/12/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Prostatic Neoplasms, Castration-Resistant, Date of authorisation: 09/12/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections;Immunization, Date of authorisation: 09/12/2009, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections;Immunization, Date of authorisation: 09/12/2009, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Kivexa, abacavir,lamivudine, HIV Infections, Date of authorisation: 16/12/2004, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Kivexa, abacavir,lamivudine, HIV Infections, Date of authorisation: 16/12/2004, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Apexxnar, pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Pneumococcal Infections, Date of authorisation: 14/02/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Apexxnar, pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Pneumococcal Infections, Date of authorisation: 14/02/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 19/11/2007, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 19/11/2007, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Somavert, pegvisomant, Acromegaly, Date of authorisation: 12/11/2002, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Somavert, pegvisomant, Acromegaly, Date of authorisation: 12/11/2002, Revision: 28, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness